For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

Phase 3 trial shows trastuzumab deruxtecan extends survival by over three months in advanced HER2-positive gastric cancer and ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

CHICAGO -- Patients with progressive HER2-positive gastroesophageal (GE) cancer lived significantly longer when they received ...

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE: AZN) have released detailed Phase III results that could help position their ...

ENHERTU Reduced Risk of Death by 30% as 2L Therapy in Patients w/HER2+ Unresectable or Metastatic Gastric Cancer in ...

AstraZeneca Plc (NASDAQ:AZN) on Monday released results from three Phase 3 clinical trials at the 2025 American Society of ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

SHA-registered beneficiaries will now have full coverage for treatment cycles costing up to Sh700,000 annually.

“Patients with HER2 positive metastatic gastric cancer who experience progression after first-line treatment have historically faced poor outcomes,” said Cristian Massacesi, MD, Chief Medical ...